Novartis AG (NVS) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medic...
Novartis AG's revenue increased 9.6% year over year, from $51.72B to $56.67B.
Net income increased 17.1% over the same period, from $11.94B to $13.98B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 29% in total.
Total debt increased by 38.2% to $49.01B.
The debt-to-equity ratio stands at 1.17, indicating a elevated leverage profile.
Operating cash flow declined 3.9% to $18.39B.
Novartis AG maintains a strong net profit margin of 24.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $43.97B | $24.02B | $32.58B | $10.96B | $14.24B | $117.45B | $27.96B | $59.42B |
| FY2022 | $43.46B-1.2% | $6.96B | $31.88B | $9.21B | $14.46B | $99.94B | $26.44B | $46.75B |
| FY2023 | $46.66B+7.4% | $14.85B | $34.19B | $10.23B | $17.62B | $102.25B | $31.40B | $44.13B |
| FY2024 | $51.72B+10.8% | $11.94B | $38.91B | $16.32B | $19.14B | $110.95B | $35.46B | $46.55B |
| FY2025 | $56.67B+9.6% | $13.98B | $43.05B | $19.00B | $18.39B | $122.03B | $49.01B | $41.95B |
Balance Sheet Summary (FY2025)
Novartis AG (NVS) Financial Statements & Revenue History
Novartis AG (NVS) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $148.40 with a market capitalization of $282. This page provides 5 historical financial statements for Novartis AG, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Novartis AG reported revenue of $56.7 billion, representing 9.6% year-over-year growth. The net profit margin of 24.7% reflects strong profitability. The debt-to-equity ratio of 1.17 indicates elevated leverage.
NVS Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Novartis AG's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether NVS is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track NVS's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Novartis AG converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of NVS's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use NVS Financial Data
Investors use Novartis AG's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare NVS's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how NVS's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View NVS's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Novartis AG's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.NVS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.